This was investigated using the selective FAAH inhibitor URB597 administered to FTD mice from pre-symptomatic phases (PND45) to symptomatic stages (PND90), and analysing the behavioural status of these mice at PND60 and PND90, as well as those histopathological markers that were found to be altered in the progression of FTD at PND90. Here, FAAH is linked to frontotemporal dementia.